Publications by authors named "Dana Enkusson"
[This corrects the article DOI: 10.1093/rap/rkaa070.][This corrects the article DOI: 10.
View Article and Find Full Text PDFArticle Synopsis
- Ustekinumab and secukinumab are shown to have different effectiveness in maintaining treatment in patients with psoriatic arthritis (PsA) compared to adalimumab, with ustekinumab generally resulting in better persistence.
- A study analyzed data from over 4,600 treatment exposures among nearly 4,000 PsA patients to compare non-persistence rates using statistical models and methods.
- Risk factors for lower drug persistence included being female, having axial involvement, recent disease onset, and prior biologic treatment experience, highlighting the importance of considering these factors in treatment planning.
This study aimed to identify if antipsychotic exposure in offspring is associated with psychiatric and non-psychiatric healthcare service use and work disability of their parents. This Swedish population-based cohort study was based on data comprising 10,883 individuals with schizophrenia, who had at least one identifiable parent in the nationwide registers, and their parents (N = 18,215). The register-based follow-up during 2006-2013 considered the level of antipsychotic exposure and persistence of use of the offspring, further categorized into first (FG) and second generation (SG) antipsychotics, and orals versus long-acting injections (LAIs).
View Article and Find Full Text PDFBackground: The study aimed to (1) compare the risk of health care use, adverse health status, and work productivity loss of parents of patients with schizophrenia to parents of patients with multiple sclerosis (MS), rheumatoid arthritis (RA), epilepsy, and healthy controls; and (2) evaluate such outcome measures while considering disease severity of schizophrenia.
Methods: Based on linkage of Swedish registers, at least one parent was included (n = 18215) of patients with schizophrenia (information 2006-2013, n = 10883). Similarly, parental information was linked to patients with MS, RA, epilepsy, and matched healthy controls, comprising 11292, 15516, 34715, and 18408 parents, respectively.
Background: Human monoclonal antibody ustekinumab is a novel Crohn's disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study's objective was to assess cost-effectiveness of ustekinumab in moderate to severely active CD in Sweden.
Methods: A cost-effectiveness model with an induction phase decision-tree structure and a maintenance phase Markov cohort structure was constructed.
Introduction: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration.
Methods: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64years with schizophrenia in Sweden (N=29,823 in total; N=4603 in the incident cohort). Multivariate Cox regression models were adjusted for clinical and sociodemographic covariates.
Importance: It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing to the impossibility of including large unselected patient populations in randomized clinical trials, as well as residual confounding from selection biases in observational studies.
Objective: To study the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia.
Design, Setting, And Participants: Prospectively gathered nationwide databases were linked to study the risk of rehospitalization and treatment failure from July 1, 2006, to December 31, 2013, among all patients in Sweden with a schizophrenia diagnosis who were 16 to 64 years of age in 2006 (29 823 patients in the total prevalent cohort; 4603 in the incident cohort of newly diagnosed patients).